Systemic Lupus Erythematosus Pipeline Analysis, 2017

  • ID: 4340254
  • Report
  • 172 pages
  • P&S Market Research
1 of 3
Pipeline Overview

Systemic lupus erythematosus is a chronic inflammatory disease that involves swelling and pain, most commonly on face. The disease affects many parts of the body including skin, joints, kidneys, pleura, pericardium and brain. The systemic lupus erythematosus is caused by impaired immune system due to which the immune system attacks its own tissues and can cause widespread inflammation and tissue damage in the affected organs. As of now there is no cure for systemic lupus erythematosus, but medical interventions and lifestyle changes can help in improving quality of life. The systemic lupus erythematosus can be mild to severe in its form. The cause of systemic lupus erythematosus is unknown, but it is most likely linked to genetic, environmental and hormonal factors. The chance of developing systemic lupus erythematosus is 10 times greater in women as compared to men.

Systemic lupus erythematosus includes symptoms such as oral ulcers, sun sensitivity, heart problems, kidney problems, psychosis, lung problems, arthritis, seizures, fevers, skin rashes, fatigue, swelling and pain in the joints. Systemic lupus erythematosus is diagnosed by examining the symptoms, physical examination, X-rays and lab tests.

Systemic lupus erythematosus treatment involves a combination approach as number of organs are involved. The treatment consists immunosuppressive drugs that inhibit activity of the immune system. The most common approach to treat systemic lupus erythematosus is the use of hydroxychloroquine and corticosteroids including prednisone.

Pipeline Analysis

As of April 2017, the systemic lupus erythematosus pipeline comprises of approximately 57 active drug candidates in different stages of development.

Competitive Landscape

Some of the key players developing drugs for systemic lupus erythematosus include Anthera Pharmaceuticals, Inc., Genentech, Inc., Merck KGaA and others.

Scope for Customization

Customization is offered as per specific business requirements of clients. Illustrative customization within the scope of this report includes:
  • Market Forecast - Market analysis and forecast for the drug candidates in the last stage of development
  • Company Profiles - Wider company coverage in terms of detailed analysis or additional company profiles
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.4 Key Stakeholders

2. Research Methodology
2.1 Secondary Research
2.2 Primary Research

3. Executive Summary

4. Pipeline Outlook
4.1 Overview
4.2 Key Drivers
4.3 Key Barriers
4.4 Systemic Lupus Erythematosus Pipeline Analysis
4.4.1 Pipeline Analysis By Phase
4.4.2 Pipeline Analysis By Target
4.4.3 Pipeline Analysis By Route Of Administration
4.4.4 Pipeline Analysis By Company

5. Systemic Lupus Erythematosus Pipeline Analysis By Phase (2017)
5.1 Phase Iii: Drug Profiles
5.1.1 Pre-Clinical Study
5.1.2 Pre-Clinical Results
5.1.3 Clinical Trials
5.1.4 Clinical Results
5.1.5 Strategic Development
5.1.6 Designation
5.1.7 Grants
5.1.8 Patent
5.1.9 Technology
5.2 Phase Ii: Drug Profiles
5.2.1 Pre-Clinical Study
5.2.2 Pre-Clinical Results
5.2.3 Clinical Trials
5.2.4 Clinical Results
5.2.5 Strategic Development
5.2.6 Designation
5.2.7 Grants
5.2.8 Patent
5.2.9 Technology
5.3 Phase I: Drug Profiles
5.3.1 Pre-Clinical Study
5.3.2 Pre-Clinical Results
5.3.3 Clinical Trials
5.3.4 Clinical Results
5.3.5 Strategic Development
5.3.6 Designation
5.3.7 Grants
5.3.8 Patent
5.3.9 Technology
5.4 Pre-Clinical: Drug Profiles
5.4.1 Pre-Clinical Study
5.4.2 Pre-Clinical Results
5.4.3 Strategic Development
5.4.4 Designation
5.4.5 Grants
5.4.6 Patent
5.4.7 Technology
5.5 Discovery: Drug Profiles
5.5.1 Strategic Development
5.5.2 Designation
5.5.3 Grants
5.5.4 Patent
5.5.5 Technology

6 Competitive Landscape
6.1 Key Players Benchmarking For Systemic Lupus Erythematosus Drug Candidates
6.2 Swot Analysis Of Systemic Lupus Erythematosus Pipeline

7 Company Profiles
7.1 Business Overview
7.2 Product And Service Offerings

8 Appendix
8.1 Abbreviations

List Of Tables
Pipeline Analysis Of Systemic Lupus Erythematosus, By Company (2017)
Description Of Phase Iii Drug Candidates
Clinical Trials Of Phase Iii Drug Candidates
Description Of Phase Ii Drug Candidates
Clinical Trials Of Phase Ii Drug Candidates
Description Of Phase I Drug Candidates
Clinical Trials Of Phase I Drug Candidates
Description Of Pre-Clinical Drug Candidates
Description Of Discovery Drug Candidates
Companies- At A Glance

List Of Figures
Research Methodology For The Systemic Lupus Erythematosus Pipeline Analysis
Split Of Primary And Secondary Research
Breakdown Of Primary Research Respondents, By Industry Participant
Breakdown Of Primary Research Respondents, By Company Type
Number Of Systemic Lupus Erythematosus Drug Candidates Under Development (2017)
Systemic Lupus Erythematosus Pipeline Split, By Target (2017)
Systemic Lupus Erythematosus Pipeline Split, By Route Of Administration (2017)
Key Players Benchmarking For Systemic Lupus Erythematosus Drug Candidates
Swot Analysis Of Systemic Lupus Erythematosus Pipeline
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll